Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
Lowenthal ED, Chapman J, Ohrenschall R, Calabrese K, Baltrusaitis K, Heckman B, Yin DE, Agwu AL, Harrington C, Van Solingen-Ristea RM, McCoig CC, Adeyeye A, Kneebone J, Chounta V, Smith-Anderson C, Camacho-Gonzalez A, D'Angelo J, Bearden A, Crauwels H, Huang J, Buisson S, Milligan R, Ward S, Bolton-Moore C, Gaur AH; IMPAACT 2017 Collaborators; IMPAACT 2017 Team. Lowenthal ED, et al. Among authors: agwu al. Lancet HIV. 2024 Apr;11(4):e222-e232. doi: 10.1016/S2352-3018(23)00301-6. Lancet HIV. 2024. PMID: 38538161 Clinical Trial.
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
Gaur AH, Capparelli EV, Calabrese K, Baltrusaitis K, Marzinke MA, McCoig C, Van Solingen-Ristea RM, Mathiba SR, Adeyeye A, Moye JH, Heckman B, Lowenthal ED, Ward S, Milligan R, Samson P, Best BM, Harrington CM, Ford SL, Huang J, Crauwels H, Vandermeulen K, Agwu AL, Smith-Anderson C, Camacho-Gonzalez A, Ounchanum P, Kneebone JL, Townley E, Bolton Moore C; IMPAACT 2017 Collaborators; IMPAACT 2017 Team. Gaur AH, et al. Among authors: agwu al. Lancet HIV. 2024 Apr;11(4):e211-e221. doi: 10.1016/S2352-3018(23)00300-4. Lancet HIV. 2024. PMID: 38538160 Clinical Trial.
Interest of Youth Living With HIV in Long-Acting Antiretrovirals.
Weld ED, Rana MS, Dallas RH, Camacho-Gonzalez AF, Ryscavage P, Gaur AH, Chakraborty R, Swindells S, Flexner C, Agwu AL. Weld ED, et al. Among authors: agwu al. J Acquir Immune Defic Syndr. 2019 Feb 1;80(2):190-197. doi: 10.1097/QAI.0000000000001896. J Acquir Immune Defic Syndr. 2019. PMID: 30418298 Free PMC article.
Uptake and virological outcomes of single- versus multi-tablet antiretroviral regimens among treatment-naïve youth in the HIV Research Network.
Griffith DC, Farmer C, Gebo KA, Berry SA, Aberg J, Moore RD, Gaur AH, Mathews WC, Beil R, Korthuis PT, Nijhawan AE, Rutstein RM, Agwu AL; HIV Research Network. Griffith DC, et al. Among authors: agwu al. HIV Med. 2019 Feb;20(2):169-174. doi: 10.1111/hiv.12695. Epub 2018 Dec 18. HIV Med. 2019. PMID: 30561888 Free PMC article.
Modeling Adherence Interventions Among Youth with HIV in the United States: Clinical and Economic Projections.
Neilan AM, Bangs AC, Hudgens M, Patel K, Agwu AL, Bassett IV, Gaur AH, Hyle EP, Crespi CM, Horvath KJ, Dugdale CM, Powers KA, Rendina HJ, Weinstein MC, Walensky RP, Freedberg KA, Ciaranello AL. Neilan AM, et al. Among authors: agwu al. AIDS Behav. 2021 Sep;25(9):2973-2984. doi: 10.1007/s10461-021-03169-0. Epub 2021 Feb 6. AIDS Behav. 2021. PMID: 33547993 Free PMC article.
87 results